399 related articles for article (PubMed ID: 34022697)
1. Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
Keil F; Hartl M; Altorjai G; Berghold A; Riedl R; Pecherstorfer M; Mayrbäurl B; De Vries A; Schuster J; Hackl J; Füreder T; Melchardt T; Burian M; Greil R
Eur J Cancer; 2021 Jul; 151():201-210. PubMed ID: 34022697
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
Hitt R; Mesía R; Lozano A; Iglesias Docampo L; Grau JJ; Taberna M; Rubió-Casadevall J; Martínez-Trufero J; Morillo EDB; García Girón C; Vázquez Estévez S; Cirauqui B; Cruz-Hernández JJ
Oral Oncol; 2022 Nov; 134():106087. PubMed ID: 36126605
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
[TBL] [Abstract][Full Text] [Related]
4. Induction Chemotherapy With 5-Fluorouracil, Cisplatin, and Cetuximab in Advanced Head and Neck Squamous Cell Carcinoma.
Yamauchi M; Minesaki A; Ishida T; Sato Y; Okamura S; Shuto H; Tanaka N; Hatayama E; Shibamiya N; Kuratomi Y
In Vivo; 2023; 37(3):1275-1280. PubMed ID: 37103108
[TBL] [Abstract][Full Text] [Related]
5. Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.
Hsieh CY; Lein MY; Yang SN; Wang YC; Lin YJ; Lin CY; Hua CH; Tsai MH; Lin CC
BMC Cancer; 2020 Sep; 20(1):832. PubMed ID: 32873270
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil.
Shirasu H; Yokota T; Kawakami T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Mori K; Onitsuka T
Int J Clin Oncol; 2020 Nov; 25(11):1914-1920. PubMed ID: 32648132
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
[TBL] [Abstract][Full Text] [Related]
8. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
Trieu V; Pinto H; Riess JW; Lira R; Luciano R; Coty J; Boothroyd D; Colevas AD
Oncologist; 2018 Jul; 23(7):764-e86. PubMed ID: 29540603
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
Hitt R; Iglesias L; López-Pousa A; Berrocal-Jaime A; Grau JJ; García-Girón C; Martínez-Trufero J; Guix M; Lambea-Sorrosal J; Del Barco-Morillo E; León-Vintró X; Cunquero-Tomas AJ; Baste N; Ocaña A; Cruz-Hernández JJ;
Clin Transl Oncol; 2021 Apr; 23(4):764-772. PubMed ID: 32797376
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients.
Szturz P; Vinches M; Remenár É; van Herpen CML; Abdeddaim C; Stewart JS; Fortpied C; Vermorken JB
Eur J Cancer; 2021 Oct; 156():109-118. PubMed ID: 34425403
[TBL] [Abstract][Full Text] [Related]
11. Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer.
Okano S; Enokida T; Onoe T; Ota Y; Motegi A; Zenda S; Akimoto T; Tahara M
Int J Clin Oncol; 2019 Jul; 24(7):789-797. PubMed ID: 30796560
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
13. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions.
Haddad RI; Posner M; Hitt R; Cohen EEW; Schulten J; Lefebvre JL; Vermorken JB
Ann Oncol; 2018 May; 29(5):1130-1140. PubMed ID: 29635316
[TBL] [Abstract][Full Text] [Related]
14. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
Specenier PM; Remenar E; Buter J; Schrijvers DL; Bergamini C; Licitra LF; Awada A; Clement PM; Fortpied C; Menis J; Vermorken JB
Ann Oncol; 2017 Sep; 28(9):2219-2224. PubMed ID: 28911062
[TBL] [Abstract][Full Text] [Related]
15. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.
Paccagnella A; Ghi MG; Loreggian L; Buffoli A; Koussis H; Mione CA; Bonetti A; Campostrini F; Gardani G; Ardizzoia A; Dondi D; Guaraldi M; Cavallo R; Tomio L; Gava A;
Ann Oncol; 2010 Jul; 21(7):1515-1522. PubMed ID: 20032123
[TBL] [Abstract][Full Text] [Related]
16. A prospective phase II randomized study of docetaxel combined with lobaplatin versus TPF regimen induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
Zhang M; Chen Y; Wu W; Jin F; Li Y; Long J; Luo X; Gong X; Chen X; Liu L; Tang H; Wang Z
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18081-18091. PubMed ID: 37985501
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
[TBL] [Abstract][Full Text] [Related]
18. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Katori H; Tsukuda M; Watai K
Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
Guo Y; Luo Y; Zhang Q; Huang X; Li Z; Shen L; Feng J; Sun Y; Yang K; Ge M; Zhu X; Wang L; Liu Y; He X; Bai C; Xue K; Zeng Y; Chang X; Chen W; Lin T
Eur J Cancer; 2021 Oct; 156():35-45. PubMed ID: 34418665
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108).
Klinghammer K; Gauler T; Dietz A; Grünwald V; Stöhlmacher J; Knipping S; Schroeder M; Guntinas-Lichius O; Frickhofen N; Lindeman HW; Fietkau R; Haxel B; Große-Thie C; Maschmeyer G; Zipfel M; Martus P; Knoedler M; Keilholz U
Eur J Cancer; 2019 Nov; 122():53-60. PubMed ID: 31618704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]